BiomX Inc. (NYSEAMERICAN:PHGE) Sees Large Increase in Short Interest

BiomX Inc. (NYSEAMERICAN:PHGE) was the recipient of a significant growth in short interest in the month of January. As of January 30th, there was short interest totaling 270,744 shares, a growth of 426.4% from the January 15th total of 51,433 shares. Currently, 17.5% of the company’s stock are short sold. Based on an average daily trading volume, of 5,798,754 shares, the short-interest ratio is currently 0.0 days. Based on an average daily trading volume, of 5,798,754 shares, the short-interest ratio is currently 0.0 days. Currently, 17.5% of the company’s stock are short sold.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating on shares of BiomX in a research note on Tuesday, November 25th. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, BiomX has a consensus rating of “Buy” and an average price target of $26.00.

Institutional Trading of BiomX

A hedge fund recently bought a new stake in BiomX stock. Citadel Advisors LLC purchased a new stake in BiomX Inc. (NYSEAMERICAN:PHGE) during the third quarter, according to its most recent filing with the SEC. The firm purchased 161,781 shares of the company’s stock, valued at approximately $85,000. Citadel Advisors LLC owned 0.61% of BiomX at the end of the most recent reporting period. 40.57% of the stock is currently owned by institutional investors.

BiomX Price Performance

Shares of BiomX stock traded up $0.77 on Thursday, hitting $6.40. 132,632 shares of the company’s stock traded hands, compared to its average volume of 2,965,587. The firm’s 50-day moving average price is $3.32 and its two-hundred day moving average price is $7.06. The stock has a market capitalization of $10.18 million, a PE ratio of -0.25 and a beta of 1.66. BiomX has a one year low of $1.50 and a one year high of $22.06.

About BiomX

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.